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Available online 14 August 2016Currently, there is no available biomarker for lung cancer diagnosis. Here we recruited 844 lung cancer patients
and 620 healthy participants from six hospitals. A total of four serum proteins was identiﬁed and subsequently
assessed in the training and validation cohorts. The concentrations of four serum proteins were found to be sig-
niﬁcantly higher in lung cancer patients comparedwith healthy participants. The area under the curve (AUC) for
the 4-biomarkerwere 0.86 in the training cohort, and 0.87 in the validation cohort. The classiﬁcation improved to
a corrected AUC of 0.90 and 0.89 respectively following addition of sex, age and smoking status. Similar results
were observed for early-stage lung cancer. Remarkably, in a blinded test with a suspicious pulmonary nodule,
the adjusted predictionmodel correctly discriminated the patients with 86.96% sensitivity and 98.25% speciﬁcity.
These results demonstrated the 4-biomarker panel improved lung cancer prediction beyond that of known risk
factors. Moreover, the biomarkers were valuable in differentiating benign nodules which will remain indolent
from those that are likely to progress and therefore might serve as an adjuvant diagnosis tool for LDCT scanning.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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LDCT1. Introduction
Lung cancer is continuously the leading cause of cancer-related
deaths for both men and women worldwide (Cancer Facts & Fig-
ures 2015, American Cancer Society). The early detection of lung cancer
presents an opportunity to dramatically reduce disease mortality. The
overall 5-year relative survival rate was 17%; however, if the cancer is
detected at stage Ia, the 5-year survival often exceeds 80% (Mahadevia
et al., 2003). Currently, the National Lung Screening Trial (NLST) using
low dose chest computed tomography (LDCT) in high-risk individuals
demonstrates that a 20% reduction in lung cancer-speciﬁc mortality
and a 6.7% reduction in all-cause mortality can be achieved
(International Early Lung Cancer Action Program I et al., 2006; Bach
et al., 2007; Henschke et al., 1999; Sone et al., 1998). However, there
is a signiﬁcant chance of a false-positive result for CT scan, which may
require additional clinical testing, even an invasive procedure to specify
an abnormality (Welch et al., 2007; Wilson et al., 2008; Swensen et al.,
2005). Such ﬁnding greatly exacerbates the high cost of the technology
and leads to unnecessary patient anxiety and surveillance. Therefore, a
non-invasive test with a high speciﬁcity for distinguishing the indolent
disease from lung cancer patients is highly demanded.dicine, 182 Tianmushan Road,
. This is an open access article underSerumbiomarkers could beused as an invasive, cost-effectiveway to
differentiate lung cancer patients. Several serum tumor markers have
been studied extensively, such as carcinoembryonic antigen (CEA),
serum cytokeratin 19 fragments, and pro-gastrin-releasing peptide;
however, none has been demonstrated to provide clinical utility, mainly
because of the poor reproducibility and lack of sufﬁcient sensitivity and
speciﬁcity (Buccheri et al., 2003; Pastor et al., 1997).
Recently, we described a non-invasive diagnostic system on
Luminex xMAP platform to detect serum autoantibodies for diagnosis
of lung cancer (Jia et al., 2014). Given the biological properties of cancer
as a systemic disease,we predict that a combination of cancer associated
serum proteins and autoantibody can be used to achieve superior levels
of sensitivity and speciﬁcity. Here, we identiﬁed a diverse set of circulat-
ing proteins in the sera of patients with lung cancer and designed a
large-scale, multicenter validation study to evaluate their utility in
distinguishing lung cancer patients from matched healthy controls,
with the goal of using these biomarkers to aid clinicians in making
case management decisions.
2. Methods
2.1. Patients Population
The recruitment of patient with lung cancer was initiated fromMay
2009 and the discovery phase of the study included the patients collect-
ed until September 2009 from Hangzhou First People's Hospital,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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collected between February 2011 and March 2012 from 3 hospitals,
namely Hangzhou First People's Hospital, Hangzhou Cancer Hospital
and Zhejiang Cancer Hospital, Zhejiang, China. The validation lung can-
cer patients were recruited from September 2012 to December 2013
from 6 hospitals, including the 3 hospitalsmentioned in the training co-
hort, and the First Hospital of Jiaxing, the First Afﬁliated Hospital of
Wenzhou Medical University, Shaoxing People's Hospital, Zhejiang,
China.
Approval for the study was obtained from the institutional ethics re-
view committee. All patients were provided written informed consent,
according to the committees' regulations.2.2. Patient and Serum Collection
The patients included in this studywere all consecutive patients, and
details regarding patient inclusion criteria and collection protocols have
been previously reported (Jia et al., 2014). All cases used in this study
were conﬁrmed to be primary lung cancer by pathology review.
Healthy participants were recruited from the eligible blood donors
with no evidence of pulmonary disorders of any type andwere approx-
imately age and sex-matched to the cancer cohorts presented. Patients
who had a history of other solid tumors were excluded from the study.2.3. Cancer Biomarker Screening and Detection
In discovery phase, samples were analyzed using the Bio-Plex Pro
Biomarker Assays (Bio-Rad Laboratories), according to the manufac-
turer's instruction. CEA concentrations were measured with commer-
cial ELISA (Roche), according to the manufacturer's recommendations.
All measurements were done in duplicate.2.4. Autoantigen Coupling to Luminex Microsphere and Detection of Auto-
antibody in Serum
The cDNA for NY-ESO-1 was cloned into the Flexi vector with a HQ-
tag at N-terminus (Promega, USA) as previously described (Jia et al.,
2014). The recombinant protein was expressed and puriﬁed using Ni-
NTA agarose (Life Technologies) according to manufacturers' protocols.
The purity was determined as N95% by SDS-PAGE and Coomassie
staining.
A total of 25 μg of puriﬁed protein was conjugated to microspheres
by following the manufacture's protocol (Luminex, Austin). The micro-
spheres conjugated with recombinant proteinwere aliquoted into a 96-
well plate, and autoantibody in serum was detected by a Bio-Plex 200
System as previously described (Jia et al., 2014). All values reported
are the raw median ﬂuorescence intensities (MFI).2.5. Calibrator for Autoantibody Measurement
Autoantibody in serum was detected by a Bio-Plex 200 System as
previously described (Jia et al., 2014). Currently, there are no calibration
standards for assays to measure cancer autoantibodies. Therefore, a
modiﬁed calibration system was adopted based on a previous publica-
tion (Murray et al., 2010). Brieﬂy, serum samples from lung cancer pa-
tients were screened for the autoantibody against NY-ESO-1 as
described above. The positive sera were then further conﬁrmed by
western blot. For each serum sample, a calibration curve of
background-corrected MFI versus log dilution was constructed to
which a four-parameter logistic model plot was ﬁtted. The MFI value
for each unknown sample was then converted to a calibrated reference
unit (RU) using the calibration curve. A calibration curve was prepared
at the beginning of every assay run.2.6. Statistical Analysis
In the discovery phase, the differences of the circulating concentra-
tions of each biomarker between two groups were evaluated by the
Mann-Whitney U test (continuous variables and nonparametric analy-
ses). R version 3.0.1, 2-sided tests and a signiﬁcance level of 0.05 were
used. If not stated otherwise, we considered all patients with lung can-
cer as a single group regardless of stage.
For the training and validation cohorts, statistical analyses were car-
ried out withMedCalc (version 15.8). Receiver operating characteristics
(ROC) curves were used to quantify the biomarker performance by
means of sensitivity, speciﬁcity, area under the curve (AUC) as well as
corresponding 95% conﬁdence intervals. To test the diagnostic accuracy
of the panel of biomarkers, we estimated functions of the combined
markers by logistic regression with or without adjustment for known
risk factors for lung cancer (age, sex and smoking status), and the pre-
dictive probabilities were used as one marker and subjected to ROC
analysis. We investigated the optimum cutoff value for diagnosis by
maximizing the sum of sensitivity and speciﬁcity and minimizing the
overall error (square root of the sum [1-sensitivity]2 + [1-speciﬁcity]2),
and byminimizing the distance of the cutoff value to the top-left corner
of the ROC curve.We also reported adjusted p-values corrected formul-
tiple testing using the Benjamini-Holm method to control for the false
positive error rate.
The correlation between the biomarkers in serum and clinicopatho-
logical characteristics was analyzed with Fisher's exact test. We took
p b 0.05 (two sided) to be signiﬁcant.
2.7. Prediction of Blinded Patients
The serum samples were collected pre-surgery from Hangzhou First
People's Hospital, Zhejiang, China. The biomarkers were measured as
described above, and the blinded patients were predicted as cancer or
non-cancer by the BRB-Array Tools package (version 3.6) available at
http://linus.nci.nih.gov/BRB-ArrayTools.html. Brieﬂy, a predictor
model was created using the 4-biomarker panel after adjustment for
age, sex and smoking status in the training set, then subsequently tested
in the validation cohort. A log base 2 transformation was applied to the
raw data. Each sample's value was multiplied by the corresponding co-
efﬁcients derived from univariate logistic regressions on the training set
with cancer/non-cancer as a binary response variable, and then the
values were totaled. The adjusted index scores were then assessed by
the ROC curve, which provided a pure index of a test's accuracy by plot-
ting the sensitivity against 1-speciﬁcity for each result value of the test.
We computed themisclassiﬁcation error of themodels using leave-one-
out cross-validation (LOOCV) method. For each LOOCV training set, the
entire model-building process was repeated, including the biomarker
selection process. The class labels were randomly permuted (100 per-
mutations), and the entire LOOCV process was repeated. The signiﬁ-
cance level is the proportion of the random permutations that gave a
cross-validated error rate no greater than the cross-validated error
rate obtained with the real data. Each clinical sample was predicted to
cancer or non-cancer group by themodel.We computed a statistical sig-
niﬁcance level (p b 0.05) for each biomarker.
3. Results
A total of 844 patients with lung cancer were included in this study,
40 in the discovery cohort, 543 in the training cohort and 261 in the val-
idation cohort (Fig. 1). The healthy controls included 620healthy partic-
ipants. There is no signiﬁcant difference in term of age and sex in both
case and control groups, however, more current smokers in cases than
controls. Clinicopathological characteristics of the study participants
are summarized in Table 1. We also recruited 70 patients with various
benign lung diseases, and 80 blinded patients with suspicious pulmo-
nary nodule detected by LDCT. All these high-risk patients were either
1614 participants enrolled
844 training cohort
543 patients (3 hospitals collected 
from  Feb 2011 to Mar 2012)
(all with CEA values and 
pathology)
301 healthy participants 
(all with CEA values)
85 discovery cohort
40  cases of confirmed lung  
cancer  (1 hospital 
collected from May-Sep, 
2009)
45 healthy participants
535 validation cohort
261 patients (multiple hospitals 
collected from Sep 2012 to 
Dec 2013) (all with CEA 
values and pathology)
274 healthy participants
(all with CEA values)
26  excluded
23 patient (unidentified pathology)
3 healthy (abnormal chest image)
1640 participants screened
150 blinded patients
80 with pulmonary 
nodule detected 
by LDCT
70 with various lung 
diseases
Fig. 1. Study design.
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CT image progressed.
Our objective for the discovery phasewas to identify a robust subset
of biomarkers to discriminate the patients with lung cancer from the
matched controls. Of the 20 circulating proteins evaluated in our study
(Supplementary Fig. 1), three proteins, namely C-reactive protein
(CRP), prolactin and hepatocyte growth factor (HGF),were found to dif-
fer signiﬁcantly between the lung cancer and control group (p b 0.01)
(Fig. 2A). Previously, we had demonstrated that circulating autoanti-
body against cancer-testis antigen NY-ESO-1 had the potential to sepa-
rate patients with lung cancer from healthy participants in a
multivariate statistical model (Jia et al., 2014). In this study, we further
validated its performance and found that NY-ESO-1 autoantibody was
signiﬁcantly higher in patients with lung cancer than healthy controls
(p b 0.05) (Fig. 2A), indicating its discriminatory utility for lung cancer
detection.
The panel of 4 biomarkers consisted of three serumproteins and one
autoantibody was further analyzed in the training and validation co-
horts to determine their clinical utilities for non-invasive detection of
lung cancer in a larger set of cases and controls. Importantly, the bio-
markers were elevated in the cases with lung cancer in the trainingTable 1
Demographics of patients and healthy participants in the discovery, training and validation coh
No. (%) of patients and healthy participants
Discovery cohort (n = 85) Training c
Cases (n = 40) Controls (n = 45) Cases (n =
Sex
Men 22 (55) 27 (60) 380 (70)
Women 18 (45) 18 (40) 163 (30)
Age at enrollment, years
b60 16 (40) 19 (42) 221 (41)
≥60 24 (60) 26 (58) 322 (59)
Smoking history
Former 1 (2) 60 (11)
Current 24 (60) 26 (58) 271 (50)
Never 12 (30) 14 (32) 195 (36)
Missing 3 (8) 5 (10) 17 (3)
Cancer stage
I 5 (13) 54 (10)
II 4 (10) 61 (11)
III 11 (27) 129 (24)
IV 16 (40) 233 (43)
Unknown 4 (10) 66 (12)
Tumor type
Adenocarcinoma 15 (38) 168 (31)
Squamous cell carcinoma 16 (40) 185 (34)
Large-cell carcinoma 1 (2) 27 (5)
Small-cell carcinoma 3 (8) 98 (18)
Non-small-cell carcinoma, unspeciﬁed 5 (12) 65 (12)
P value calculated using χ2 test.set than in the controls with a p value b 0.05. The scatter dot plots of
these biomarkers appear in Fig. 2. Themean concentrations for CRP, Pro-
lactin, HGF and NY-ESO-1 antibody in cancer group vs control group of
the population are 18.20 μg/mL (95% CI 16.59–19.80) vs 5.03 μg/mL
(95% CI 4.11–5.90), 1.27 ng/mL (95% CI 1.19–1.34) vs 1.03 ng/mL (95%
CI 0.96–1.11), 0.36 ng/mL (95% CI 0.33–0.38) vs 0.22 ng/mL (95% CI
0.21–0.23) and 2.19 RU (95% CI 1.75–2.61) vs 1.06 RU (95% CI 1.02–
1.10), respectively. As expected, the mean concentration of CEA in
serum was higher in the cancer group compared with that in healthy
controls (p b 0.001). There is no correlation between the 4 biomarkers
and the clinical factors, such as gender, age and smoking status (Supple-
mentary Table 1).
To assess if these biomarkers could predict subsequent diagnosis of
lung cancer, we performed association study between the variables
and lung cancer. In multivariable logistic regression analyses among
all participants from both training and validation sets, the serum levels
for the 4 biomarkers were statistically signiﬁcantly associatedwith lung
cancer (all p value b 0.05) (Table 2). We next examined if the associa-
tions between the 4 biomarkers and lung cancer were independent of
factors that could potentially inﬂuence the associations. Results
remained statistically signiﬁcant after adjustment for age, gender, andorts.
ohort (n = 844) P Validation cohort (n = 535) P
543) Controls (n = 301) Cases (n = 261) Controls (n = 274)
0.19 0.75
238 (79) 188 (72) 206 (75)
63 (21) 73 (28) 68 (25)
0.89 0.99
124 (42) 96 (37) 104 (38)
177 (58) 165 (63) 170 (62)
b0.001 0.002
82 (27) 20 (8) 52 (19)
102 (34) 113 (43) 104 (38)
108 (36) 99 (38) 93 (34)
9 (3) 29 (11) 25 (9)
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Fig. 2. Scatter dot blots of the biomarker concentration in serum in the discovery, training, and validation cohorts. (A) Discovery cohort. (B) Training cohort. (C) Validation cohort. The
horizontal long line in each blot indicates the mean, while the top and bottom shorter lines mark the SEM. P values were calculated by Mann-Whitney test. LC = lung cancer, HC =
healthy control.
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tween the 4 biomarkers and lung cancer were independent of these
tested potential confounding factors.
The performance of these biomarkers, in combination, in
distinguishing lung cancer patients from healthy controls was further
evaluated by receiver operating characteristic (ROC) analysis in both
training and validation sets. We estimated functions of the combined
marker by logistic regression, and used the parameters in the training
set to further evaluate in the validation set. With an optimal YoudenTable 2
Association of the serum levels for 4 serum biomarkers with lung cancer with or without
adjustment for the risk factors in both training and validation cohorts.a
Variable ORb (95% CI) P valueb ORc (95% CI) P valuec
Sex 1.03 (0.72–1.49) 0.851
Age 1.02 (1.00–1.03) 0.028
Smoke b0.001
Never Reference
Former 1.78 (1.09–2.91) b0.001
Current 3.12 (2.13–4.58) 0.020
Prolactin 2.05 (1.56–2.68) b0.001 2.01 (1.48–2.75) b0.001
CRP 1.07 (1.05–1.08) b0.001 1.06 (1.04–1.08) b0.001
NY-ESO-1 1.30 (1.08–1.56) 0.005 1.32 (1.03–1.68) 0.026
HGF 3.49 (2.06–5.88) b0.001 2.50 (2.04–4.79) b0.001
a CI = conﬁdence interval; OR = odds ratio.
b Model containing the 4-marker panel (continuous).
c Model containing sex (Male, Female), age at enrollment (continuous), smoking status
(Never, Former, Current) and the 4-marker panel (continuous).index score of 0.6145, the AUC of the 4-marker panel in the training
set was 0.86 (95% CI: 0.83–0.88). The optimal sensitivity and speciﬁcity
were 69.98% and 87.04%, respectively (Table 3). On the basis of the cut-
off index score, we evaluated both training and validation samples in
this study. The optimal cutoff value for CEAwas 3.72 μg/mL in the train-
ing set (AUC 0.768, 0.738–0.796, sensitivity 57.83%, speciﬁcity of
86.38%). Notably, the biomarkers appeared to have similar diagnostic
accuracies for SCLC or NSCLC (Supplementary Figs. 2 and 3). The detail
predictive values and likelihood ratios for the biomarkers in the diagno-
sis of lung cancer and subtypes of the patients are shown in Table 3.
To assess the extent to which the 4-biomarker panel improves over
current risk factor models, we ﬁt the logistic regression model with the
4-marker panel and adjusted for main lung cancer risk factors, namely
sex, age at enrollment, and smoking status. We found the discriminato-
ry power attributable to the 4-marker panel is substantial compared
with that of the main lung cancer risk factors (Fig. 3). The AUCs for
the full logistic models with and without the 4-marker panel in the
training cohort were 0.90 (95%CI: 0.87–0.93) and 0.70 (95%CI:
0.65–0.75), respectively. The predictive value was of similar magnitude
(AUC: 0.90; 95% CI: 0.87–0.93) when considering the current smokers
only. Notably, even though derived from both histological types, the ad-
justed 4-marker panel performed equally well in both SCLC (AUC: 0.92)
and NSCLC (AUC: 0.90). To assess the differential ability of the bio-
markers on early-stage of lung cancers, we focused on 115 (21%) of
543 patients in the training cohort with stage I & II disease. The adjusted
predictor performed well in differential diagnosis of early-stage lung
cancer from all controls, with an AUC of 0.91 (Fig. 3 and Table 3).
Table 3
Performance of the 4-biomarker panel (with or without adjustment) on detection of lung cancer in both training and validation cohorts.
Training Validation
AUC (95%
CI)
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Positive
LR
Negative
LR
AUC (95%
CI)
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Positive
LR
Negative
LR
All LC vs HC
4-marker 0.86 (0.83–0.88) 69.98 87.04 90.7 61.6 5.40 0.34 0.87 (0.83–0.89) 69.35 87.23 83.8 74.9 5.43 0.35
Adj 4-markera 0.90 (0.87–0.93) 88.16 80.43 93.7 67.3 4.51 0.15 0.89 (0.86–0.93) 85.12 78.91 87.1 75.9 4.04 0.19
CEA 0.76 (0.73–0.79) 57.83 86.38 88.5 53.2 4.25 0.49 0.80 (0.76–0.83) 55.17 94.16 90.0 68.8 9.45 0.48
4-marker+CEA 0.91 (0.89–0.93) 81.95 83.72 90.1 72.0 5.03 0.22 0.93 (0.91–0.95) 80.84 90.51 89.0 83.2 8.52 0.21
SCLC vs HC
4-marker 0.86 (0.82–0.89) 69.44 87.04 39.1 96.0 5.36 0.35 0.85 (0.80–0.89) 73.68 87.23 28.6 98.0 5.77 0.30
Adj 4-markera 0.92 (0.87–0.97) 87.50 85.21 52.8 97.3 5.92 0.15 0.88 (0.79–0.96) 86.67 72.67 22.8 98.3 3.17 0.18
CEA 0.74 (0.69–0.79) 58.33 86.38 33.9 94.5 4.28 0.48 0.67 (0.61–0.72) 42.11 94.16 33.3 95.9 7.21 0.61
4-marker+CEA 0.88 (0.84–0.91) 80.56 83.72 37.2 97.3 4.95 0.23 0.90 (0.86–0.93) 63.16 90.51 31.6 97.3 6.66 0.41
NSCLC vs HC
4-marker 0.85 (0.82–0.88) 68.60 87.04 85.2 71.8 5.29 0.36 0.86 (0.83–0.90) 71.43 87.23 74.1 85.7 5.59 0.33
Adj 4-markera 0.90 (0.87–0.93) 87.54 82.84 89.7 79.5 5.10 0.15 0.90 (0.86–0.94) 88.33 78.26 75.2 90.0 4.06 0.15
CEA 0.77 (0.73–0.80) 57.62 86.38 82.2 65.2 4.23 0.49 0.83 (0.79–0.87) 59.29 94.16 83.8 81.9 10.15 0.43
4-marker+CEA 0.91 (0.88–0.93) 81.40 83.72 84.5 80.5 5.00 0.22 0.94 (0.91–0.96) 84.29 90.51 81.9 91.9 8.88 0.17
Stage I & II LC vs HC
4-marker 0.84 (0.81–0.88) 62.61 87.04 64.9 85.9 4.83 0.43 0.84 (0.80–0.88) 64.29 87.23 50.7 92.3 5.03 0.41
Adj 4-markera 0.91 (0.87–0.94) 83.17 86.98 79.2 89.6 6.39 0.19 0.88 (0.83–0.94) 76.6 86.3 62.1 92.7 5.61 0.27
CEA 0.69 (0.64–0.73) 42.61 86.38 54.4 79.8 3.13 0.66 0.76 (0.71–0.81) 44.64 94.16 61.0 89.3 7.65 0.59
4-marker+CEA 0.87 (0.84–0.90) 73.04 83.72 63.2 89.0 4.49 0.32 0.93 (0.90–0.95) 75.00 90.51 61.8 94.7 7.90 0.28
Stage III & IV LC vs HC
4-marker 0.87 (0.84–0.89) 72.88 87.04 87.2 72.5 5.62 0.31 0.87 (0.84–0.90) 69.66 87.23 78.0 81.6 5.45 0.35
Adj 4-markera 0.91 (0.88–0.94) 84.82 86.98 92.1 76.2 6.52 0.17 0.91 (0.88–0.94) 86.99 80.75 80.4 87.2 4.52 0.16
CEA 0.78 (0.74–0.81) 60.55 86.38 84.4 64.4 4.45 0.46 0.80 (0.76–0.84) 55.62 94.16 86.1 76.6 9.52 0.47
4-marker+CEA 0.92 (0.90–0.94) 85.21 83.72 86.4 82.4 5.23 0.18 0.93 (0.90–0.95) 81.46 90.51 84.8 88.3 8.58 0.20
HC = healthy control. LC = lung cancer. SCLC = small cell lung cancer. NSCLC = non-small cell lung cancer.
a Model corrected by sex (Male, Female), age at enrollment (continuous), smoking status (Never, Former, Current) and the 4-marker panel (continuous).
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CEA. The 4-biomarker panel had greater AUC, sensitivity, and speciﬁcity
than did CEA in patients with lung cancer compared with healthy
controls (Fig. 3, Table 3). A greater proportion of patients in the training
cohort were positive for the 4-biomarker than for CEA only (380 [70.0%]
vs 314 [57.8%] of 543patients; Fig. 3). In addition, 72.9% (229out of 314)
of CEA-positive patients with lung cancer and 70.3% (161 out of 229)
of CEA-negative patients had positive 4-biomarker results, indicating
the diagnostic ability of the 4-biomarker irrespective of CEA status.
Multiplexing the 4-marker panel and CEA remarkably increased the
diagnostic accuracy for lung cancer compared with either biomarker
alone (AUC 0.913, 95% CI 0.892–0.931, sensitivity 81.9% and speciﬁcity
83.7%; 4-marker + CEA vs 4-marker alone, p b 0.0001; 4-marker + CEA
vs CEA alone, p b 0.0001; Table 3). Likewise, a much higher proportion
of patients with early-stage lung cancer had positive results for the
4-biomarker than for CEA, and similar proportion of patients had posi-
tive 4-biomarker results for both CEA-negative patients (38 [60.8%] of
66) and CEA-positive patients (34 [61.4%] of 49) (Fig. 3). Diagnostic
accuracy using 4-marker + CEA remained improved in the detection
of early-stage lung cancer as well as other lung cancer subgroups
(Fig. 3, Table 3).
In order to further assess the speciﬁcity of the 4-biomarker panel in
detecting lung cancer patients, we collected a group of patientswith be-
nign lung diseases, including granuloma, pulmonary inﬂammatory
pseudotumor, tuberculosis, pulmonary nodule and sequestration. Of
note, these patients were diagnosed based on the clinical examination
with 2 years of following up. Supplementary Table 2 demonstrated
the clinical characteristics of these patients. Interestingly, of the 70 pa-
tients with benign lung diseases, 56 patients (4/6 granuloma, 4/4
pseudotumor, 8/10 pulmonary nodule, 1/2 sequestration, and 39/48 tu-
berculosis) were classiﬁed as benign by the adjustedmodel, resulting in
a speciﬁcity of 80% (Supplementary Table 3), indicating the robustness
of the biomarkers in detecting the patients with benign lung diseases.We next investigated the potential clinical application of the
4-biomarker panel in predicting the blinded patient samples. The
clinical characteristics of the 80 patients are demonstrated in Table 4
and the median sizes of nodule are 1.7 cm and 0.54 cm for cases and
controls respectively. All patients received blood drawn before any in-
vasive clinical intervention. The measurement of the 4 biomarkers and
the generation of the adjusted prediction model were as described
above. Table 5 showed the prediction of the patients as well as the
predictive values and likelihood ratios. Importantly, of the 23 lung can-
cer patients validated by pathology, 20 individuals were classiﬁed as
cancers, while 56 non-cancer patients as followed for 2 years were
predicted as benign, which resulted in 86.96% sensitivity and 98.25%
speciﬁcity. Fig. 4 showed the representative CT images from three
patients as well as hematoxylin and eosin stained tissue sections after
surgery. These results are very intriguing as the high speciﬁcity indi-
cates that the 4-biomarker panel has robust discriminatory power in
distinguishing indolent diseases from early-stage patients with lung
cancer and thereforemight serve as an adjuvant non-invasive diagnosis
tool for unspeciﬁed pulmonary abnormalities by CT screening.
Using the same index scores for all the variables in logistic regression
model as in the training set,we observed similar results in the validation
cohort to those in the training cohort. The 4-marker panel had signiﬁ-
cantly higher diagnostic accuracy for all lung cancer, early-stage lung
cancer as well as other cancer subtypes. In addition, the 4-marker was
able to detect lung cancer in CEA-negative patients from the validation
cohort, especially those with early-stage disease. The improvement in
diagnostic accuracy for lung cancer by 4-marker+CEAwas also proven
in the validation cohort (Table 3, Fig. 3).
4. Discussion
Identiﬁcation of blood-based biomarkers has been previously re-
ported. A pre-speciﬁed 22 miRNA signature has signiﬁcant diagnostic
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Fig. 3. Performance of the adjusted 4-biomarker panel in the diagnosis of lung cancer. ROC curve for the adjusted 4-marker panel, CEA, and the risk factors for all patients with lung cancer
versus all controls in the training cohort (A) and validation cohort (B). The proportion of positive samples for the 4-marker panel, CEA, or their combination in all lung cancer patients, and
for the 4-marker panel by CEA status, in the training cohort (C) and validation cohort (D). ROC curve for the adjusted 4-marker panel, CEA, and the risk factors for the early stage lung
cancer patients versus all controls in the training cohort (E) and validation cohort (F). The proportion of positive samples for the 4-marker panel, CEA, or their combination in the early
stage lung cancer patients, and for the 4-marker panel by CEA status, in the training cohort (G) and validation cohort (H). ROC = receiver operating characteristics. LC = lung cancer.
HC = healthy control.
215S. Ma et al. / EBioMedicine 11 (2016) 210–218and prognostic performance, and could reduce the false-positive rate of
LDCT (Sozzi et al., 2014). A multiplexed serum protein was able to dis-
criminate clinical lung cancer patients from high-risk individuals, thushaving the potential to aid in the early detection of lung cancer
(Bigbee et al., 2012). A panel of six autoantibodies has been tested and
validated in case–control settings and may be a detection tool for
Table 4
Clinical characteristics of the blinded patients with pulmonary nodule detected by LDCT.
No. of lung cancer
patients (as
conﬁrmed by surgery)
No. of none-cancer
patients
(as followed for 2 years)
N = 23 N= 57
Sex
Men 13 23
Women 10 34
Age, median (range), y 53.5 (46–66) 53 (40–78)
Smoking history
Former 0 1
Current 8 14
Never 6 30
Missing 9 12
Nodule size, median (range),
cm
1.7 (0.5–4.12) 0.54 (0.23–2.5)
b1 7 44
1–2 10 11
2–3 5 2
N3 1
Cancer stage
I 12
II 10
Unknown 1
216 S. Ma et al. / EBioMedicine 11 (2016) 210–218early lung cancer patients (Lam et al., 2011; Jett et al., 2014). These re-
sults further ensure serum biomarkers could be a noninvasive approach
to differentiate early lung cancers.
In this study we identiﬁed a highly performing panel of protein bio-
markers in serum, and measurement of the panel had diagnostic value
for lung cancer better than that of CEA, especially for patients with
small unidentiﬁed pulmonary nodules. The signiﬁcance of the discovery
was further validated by a large-scale population (N1000) collected
from multiple hospitals/medical centers across 5 years, and the
multiplexed biomarkers have the clinical diagnostic relevance for lung
cancer, particularly for the high-risk populationwith suspicious pulmo-
nary nodules detected by CT screening (size b2 cm). The high speciﬁcity
indicate that the panel of biomarkers could be suitable for detecting
lung cancer patients, especially early stage disease, thus assisting the
physician and the patients to make decision for immediate medical in-
tervention. More importantly, this panel could be useful to guide CT
scanning to clarify the pulmonary abnormalities. In this setting, the bio-
markers would dramatically reduce the patient anxiety and the cost of
additional testing, further beneﬁting the patients as well as the public
health in all.
The protein biomarkers described in this study have all been associ-
ated with lung cancer, and characterized previously for cancer diagnos-
tic potential. The elevated CRP preceded lung cancer diagnosis by
several years (Chaturvedi et al., 2010), and were associated with in-
creasing lung cancer risk (Xu et al., 2013). Elevation of serum prolactin
could be served as diagnostic biomarkers for lung cancer (Bigbee et al.,
2012; Nolen et al., 2011). Sera HGF were signiﬁcantly elevated in lung
cancer patients (Tanaka et al., 2011), and a high level of blood HGF ex-
hibited a poor prognosis of metastatic disease in primary lung cancer
patients (Hosoda et al., 2012). NY-ESO-1 autoantibody frequencies in
lung cancer have been reported to range from 4 to 23% (ChapmanTable 5
Performance of the adjusted 4-biomarker panel on diagnosis of the blinded patients. The predic
status (Never, Former, Current) and the 4-marker panel (continuous).
Patients with pulmonary nodule
Cancer (as conﬁrmed by
surgery)
Non-cancer (as followed for 2
years)
Classiﬁed as cancer 20 1
Classiﬁed as non-cancer 3 56et al., 2008; Tureci et al., 2006; Stockert et al., 1998). More importantly,
NY-ESO-1 autoantibodywas detected in patientswith small primary tu-
mors and more frequently before distant metastasis occurred, suggest-
ing that NY-ESO-1 antibody is an early event (Tureci et al., 2006).
Although the biomarker panel we described here could not detect
every lung cancer patient, it offers a high speciﬁcity in detecting healthy
controls as well as the patients with benign lung diseases. After the ap-
propriate conﬁrmatory clinical trials, one could envision that the most
immediate scenario in which this panel could be used is to improve in-
terpretation of CT images in the setting of a suspicious pulmonary nod-
ule. In this context, a diagnostic biomarker panel must perform at a
maximal level of speciﬁcity in order to reduce the number of false pos-
itive results rendered by CT. Actually, of the 80 prospective patients, the
4-biomarker predictor produced 82.6% sensitivity and 98.2% speciﬁcity
as determined by post-surgery histologic results or 2 years clinical
follow-up. Therefore, as a supplementary diagnostic approach to CT
scan, such a strategy could signiﬁcantly reduce the number of futile in-
vasive procedures. Upon further validation and optimization, these
serum biomarkers could provide an effective means to further assess
the malignant patients designated as having a high risk for lung cancer
by LDCT scanning.
5. Conclusions
This study identiﬁed 4 serum biomarkers that had the ability to dis-
tinguish patients with lung cancer from benign controls. These bio-
markers have potential to aid in detecting early stage of lung cancer
and more accurate interpretation of the pulmonary abnormalities,
thus serving as an adjuvant diagnosis tool for LDCT screening. Although
we validated the panel, our ﬁndings are preliminary. Further study is
necessary to validate whether the 4-biomarker panel alone has clinical
implications as a screening test for early diagnosis of lung cancer.
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